Yüklüyor......
Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemical...
Kaydedildi:
| Yayımlandı: | Mol Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7087479/ https://ncbi.nlm.nih.gov/pubmed/32257197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2014 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|